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Abstract
Mitochondria are the energy producing organelles of the cell, and mutations within their genome can cause numerous and
often severe human diseases. At the heart of every mitochondrion is a set of five large multi-protein machines collectively
known as the mitochondrial respiratory chain (MRC). This cellular machinery is central to several processes important for
maintaining homeostasis within cells, including the production of ATP. The MRC is unique due to the bigenomic origin of its
interacting proteins, which are encoded in the nucleus and mitochondria. It is this, in combination with the sheer number of
protein-protein interactions that occur both within and between the MRC complexes, which makes the prediction of
function and pathological outcome from primary sequence mutation data extremely challenging. Here we demonstrate
how 3D structural analysis can be employed to predict the functional importance of mutations in mtDNA protein-coding
genes. We mined the MITOMAP database and, utilizing the latest structural data, classified mutation sites based on their
location within the MRC complexes III and IV. Using this approach, four structural classes of mutation were identified,
including one underexplored class that interferes with nuclear-mitochondrial protein interactions. We demonstrate that this
class currently eludes existing predictive approaches that do not take into account the quaternary structural organization
inherent within and between the MRC complexes. The systematic and detailed structural analysis of disease-associated
mutations in the mitochondrial Complex III and IV genes significantly enhances the predictive power of existing approaches
and our understanding of how such mutations contribute to various pathologies. Given the general lack of any successful
therapeutic approaches for disorders of the MRC, these findings may inform the development of new diagnostic and
prognostic biomarkers, as well as new drugs and targets for gene therapy.
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Introduction
Mitochondria are double-membrane, energy-producing organ-
elles in eukaryotic cells and contain multiple copies of their own
genome; mitochondrial DNA (mtDNA) (Figure 1A). The appara-
tus that mitochondria use to generate the majority of cellular
energy is the mitochondrial respiratory chain (MRC) located in the
inner membrane. Recent publication of the entire Complex I [1,2]
completes the set of crystal structures and examples for all five
multi-subunit protein complexes that make up the MRC are now
available (Figure 1B). Complexes I to IV transport electrons from
NADH and FADH2 to molecular oxygen in the mitochondrial
matrix. This provides sufficient energy for Complex I, III and IV
to translocate protons from the matrix to the intermembrane
space, generating a proton gradient. The flow of protons back
across the inner mitochondrial membrane to the matrix then
drives Complex V to synthesize ATP from ADP and inorganic
phosphate [3]. Many cellular processes are coupled to the electron
flow through the MRC, including regulation of nucleotide pools,
tricarboxylic acid-cycle flux, one-carbon metabolism and reactive
oxygen species (ROS) signaling (reviewed in [4]). Additionally,
several processes are coupled to the proton motive force, a
consequence of the proton gradient generated across the MRC,
including calcium transport, NADPH generation, ATP/ADP
exchange, protein import, inorganic phosphate transport and
mitochondrial membrane potential (reviewed in [4]). Disruptions
in the MRC therefore have significant capacity to affect cellular
homeostasis and phenotype.
The MRC is unique in the cell due to the bigenomic origin of its
protein subunits. Nuclear DNA (nDNA) contributes some 70
subunits and mtDNA contributes the remaining 13 subunits to the
MRC (Figure 1A&B). The mitochondrial-encoded proteins are
found within the membrane-spanning domains of each complex
and perform the principal functions of the MRC. These core
subunits contain a variety of redox centers and represent ancient
machinery that has remained relatively unchanged from its
prokaryotic origins. However, the mammalian cell environment
offers significant challenges for a regulated energy-producing
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system based on electron transfer. The evolutionary consequence,
particularly for Complex III and IV, is the synthesis of an
elaborate multi-subunit protein shell that protects the core from
oxidative damage while endowing it with exquisite control over
catalytic activity. The ordered biogenesis and assembly of these
structures involves a multitude of accessory proteins necessary for
orchestrated transcription, processing, translation, chaperoning
and assembly [5]. We focus this study on Complexes III and IV
since the availability of closely homologous high-resolution bovine
structures provides an excellent template for detailed mapping
analysis (Table 1). Furthermore, in addition to their central role in
the MRC, these two complexes represent paradigms of quaternary
protein organization and reveal the intimate relationship between
mitochondrial and nuclear-encoded subunits.
Complex III (EC 1.10.2.2) occupies the middle position of the
MRC and couples the transfer of electrons from ubihydroquinone
to cytochrome c while generating a proton gradient across the
inner mitochondrial membrane [6,7]. Complex III, which is also
known as cytochrome bc1 (Cyt bc1) and ubiquinol: cytochrome c
oxidoreductase, is a dimer where each monomer is composed of
11 different subunits [8]. There are three redox-active subunits in
each half; the iron-sulphur protein (ISP), cytochrome c1 and the
only mitochondrial-encoded subunit, cytochrome b, located
centrally in the trans-membrane region (Figure 1, gene and
protein depicted in red). These subunits harbor a Rieske-type
Fe2S2 iron-sulphur cluster and two hemes, bH and bL which
together facilitate the proton-motive Q-cycle mechanism [9].
There are two separate quinone binding sites, the Qo site for
quinone oxidation and the Qi site for reduction. There is a
bifurcated electron flow at the Qo site where two electrons are
transferred from ubihydroquinone to two different chains. The
first electron is transferred to the ISP, then onwards to cytochrome
c1 and finally to cytochrome c. The second electron is transferred
sequentially to heme bL, then bH, and onward to the ubiquinone
bound at the Qi site. Two protons are released from the
intermembrane space for every quinol oxidised. In the full
catalytic cycle, two molecules of quinol are consumed at the Qo
site, one quinol molecule is generated at the Qi site, and a total of
four protons are translocated across the mitochondrial membrane
from the matrix to the intermembrane space [10].
Complex IV (EC 1.9.3.1), or cytochrome c oxidase (COX), is
the terminal component of the MRC, which reduces molecular
oxygen to water with the electrons from the reduced form of
cytochrome c, a product of Complex III, while pumping protons
Figure 1. Architecture of the mitochondrial genome and respiratory chain. (A) Schematic representation of the 16,569 bp human
mitochondrial genome (NC_012920), with the protein-coding genes colored according to the complexes to which they contribute subunits, two
ribosomal RNAs, 22 tRNAs and non-coding D-loop in white. (B) Montage depicting the structural information currently available for the five
complexes that together contribute to the mitochondrial oxidative phosphorylation machinery. Each complex (to scale) is embedded in a cartoon
representation of the lipid bilayer with the mitochondrial (m)-encoded subunits colored corresponding to the genome diagram. The nuclear (n)-
encoded subunits are shown in grey with the relative contributions found in higher organisms detailed below.
doi:10.1371/journal.pone.0069003.g001
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from the mitochondrial matrix to the intermembrane space
[11,12]. Complex IV has three main areas: an outer region that
faces the inter-membrane space, an inner region that faces the
matrix side and a large trans-membrane region. The complex is
composed of 13 subunits: three mitochondrial-encoded subunits
that form the central core (CO1, CO2 and CO3: depicted in
yellow in Figure 1B) and 10 nuclear-encoded subunits that form a
structural scaffold around the core [13]. The complex also
contains two iron sites (heme a and a3), two copper sites (CuA
and CuB), as well as zinc and magnesium sites [14]. Electron and
proton transfers are performed by the mitochondrial-encoded
CO1 and CO2 subunits. Mitochondrial-encoded CO1 and CO2
also create the channels required for the dioxygen molecule to
reach, and the H2O molecule to be removed from, the O2
reduction site. In the complete cycle, four electrons are transferred
to molecular oxygen (O2) from four molecules of cytochrome c
producing two molecules of water. A total of four protons are
removed from the mitochondrial matrix of which two are
translocated across the membrane. In combination with Complex
I, Complexes III and IV maintain the proton gradient that is the
driving force behind ATP-generation in the MRC via the FOF1
ATP synthase [15,16].
Mutations in the genes that encode protein components of the
MRC are associated with numerous diseases, ranging from
classical mitochondrial disorders (e.g. Leber’s hereditary optic
neuropathy (LHON), Mitochondrial Encephalomyopathy, Lactic
Acidosis, and Stroke-like episodes and Leigh syndrome [17]) to
more common disorders, including neurodegenerative diseases
(e.g. Parkinson’s [18]), cancers (e.g. prostate [19]) and metabolic
diseases (e.g. obesity [20]). Large scale genomic projects, including
the Cancer Genome Atlas (TCGA), are opening up new
possibilities in the development of personalized medicine [21].
Both maternally inherited and somatic mtDNA-mutations are
increasingly being discovered, and a recent report has revealed the
spectrum of mitochondrial mutations in five cancers following the
whole-genome massively parallel sequencing of tumor and non-
tumor tissue pairs [22]. However, it is not always clear which
mitochondrial mutations are functionally relevant and contribute
to disease due to several confounding factors: 1) multiple mtDNA
molecules are resident in affected tissues and only a proportion of
these are mutated (a state referred to as heteroplasmy) [23], 2) the
number of mutant mtDNAs must exceed a certain threshold for a
functional effect to be observed, 3) the threshold at which a
phenotype is observed varies between tissues [24,25] and 4) often
multiple nuclear and mitochondrial mutations are present [22].
One way to identify whether a mtDNA mutation is pathogenic
is to demonstrate that mitochondria harboring it, either in patient
samples or transmitochondrial cybrids, have a corresponding
biochemical defect [26], however, it is simply not possible to do
this for every mutation; thus, their role in pathogenicity remains
unresolved. Computer-based algorithms can be used to evaluate
the affect of amino acid substitutions (AAS) that result from
mutations in mtDNA on protein function in silico and an integrated
approach using the SIFT (http://sift.jcvi.org) and PolyPhen
(http://genetics.bwh.harvard.edu/pph2) programs has recently
been published [27]. Similarly, MutationAssessor has recently
been used to predict the functional impact of mitochondrial AAS
in cancer [22].
SIFT and MutationAssessor are sequence homology-based
approaches and both use multiple alignments of homologous
and distantly related sequences to identify which positions are
evolutionarily conserved within and between species. If the AAS is
conserved across multiple sequences it will be deemed as
important for protein function. Polyphen uses sequence homology
together with a combination of extracted data, such as protein
function annotations from the UniProtKB database, secondary
structure information from the DSSP program [28,29], crystallo-
graphic B-factors from the RCSB Protein Databank (PDB) [30]
and calculated structural parameters including accessible surface
area, hydrophobicity and electrostatics, to arrive at a prediction. If
the alignments, annotations or basic structural parameters suggest
the AAS is conserved, buried in the protein structure or found
within an active site, a ligand-binding region, is part of a disulfide
bridge or a protein-protein interaction region, it will be predicted
as pathogenic.
Despite their predictive potential, these generic algorithms can
perform sub-optimally and yield contradictory information when
applied to the MRC. One reason is the lack of any human MRC
protein complex structures. All three programs deal with this by
utilizing sequences from lower organisms for the analysis of
sequence variation. Given the potential structural and functional
differences between the human and distantly related template
Table 1. Conservation of mitochondrial-encoded subunits within the complexes (I–V) between human and its high resolution
structural homologs.
Complex Structural Homolog (PDB No, Ref) Chain (s) H. sapiens (mt-) Homology (%)
I T. thermophilus (4HEA and 3M9S, [2,70]) H, T ND1 41
E. coli (3RKO, [1]) D, N ND2 21
A, E ND3 28
C, M ND4 28
G, K ND4L 22
B, L ND5 27
F, J ND6 12
III B. taurus (1NTZ, [10]) C CYB 78
IV B. taurus (2EIJ, [40]) A, N CO1 91
B, O CO2 75
C, P CO3 88
V E. coli (1C17, [73]) M ATP6a 23
aThere is no high resolution structural homolog for the mitochondrial-encoded ATP8 present in humans.
doi:10.1371/journal.pone.0069003.t001
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proteins, it is possible that the role of specific AAS can be missed or
misinterpreted. Although the main features of the catalytic
subunits are often widely conserved, the situation in the eukaryotic
cell is often more complicated, particularly where multiple
additional accessory subunits generate new interfaces. This is
particularly relevant when sequence information from bacterial
structural homologues of Complex I and V are used.
We therefore employed 3D structural analysis, more appropri-
ate for the bigenomic, quaternary structural organization of the
MRC, to determine the functional importance of AAS in Complex
III and IV mitochondrial proteins. We demonstrate how this
approach can be used for predicting pathogenicity and shedding-
light on disease mechanisms. Additionally, we identify four
structural classes, including an elusive and as yet underexplored
class of mitochondrial mutations that affect the assembly and
stability of the complexes studied. The work presented here
provides an extension to current methods, reveals novel interac-
tions that can underpin specific mitochondrial diseases and will
benefit those in the field that wish to predict clinical outcomes
from the wealth of emerging genetic information.
Results and Discussion
The Development of a Predictive Approach
Current available tools are extremely useful, but often yield
contradictory information when applied to mitochondrial muta-
tions, falling short of the Holy Grail which is to directly inform the
clinician of the likelihood and severity of mitochondrial syndromes
and diseases from the results of a straightforward genetic test. This
remains challenging due to the complex architecture of the protein
complexes that are encoded by the mitochondrial genome, as
shown in Figure 1, but also because there is significant cross-talk
with an array of nuclear-encoded proteins. Nevertheless, we find
ourselves in a fortunate position where there is a large collated
database of mitochondrial mutations publically available, a vast
body of literature that includes everything from patient data to
detailed biochemistry, and a complete set of MRC protein
complex crystal structures, albeit from human orthologs.
Our approach, summarized in Figure S2, involved taking all 13
human mitochondrial protein sequences to find the most
homologous protein structures currently available and this allowed
us to compile Figure 1B. We chose to model AAS in proteins that,
following alignment, were at least 60% identical between the
human sequences and the homologs identified, as this has been
shown to improve prediction accuracy [31]. For the time being,
this restricted the application of the 3D structural analysis to
mutations in mtDNA genes that encode the protein subunits for
the structurally and biochemically well-defined bovine complexes
III and IV of the MRC (Table 1 and Figure S1). Nonetheless, as
more complete MRC structural homologues become available, it
will become possible to predict the pathogenicity of the mutations
in the remaining 9 mtDNA genes, increasing the predictive power
of our approach. In parallel, the MITOMAP database was
consulted for published mutations with disease-associations and all
93 found in Complex III and IV genes were mapped onto their
bovine protein structural homologs (Figure 2). Direct biochemical
evidence from the literature was then collated to formulate a set of
mutations we call ‘Confirmed mutations’ to test our approach
(Table 2). Patient samples from this set have biochemical data that
confirm that the identified mutation causes dysfunction of the
associated protein complex in the MRC. In some cases, this is
supported by the availability of cybrid data: that is, where a cell
line containing that particular mutation has been generated and
analyzed. The set of ‘Confirmed mutations’ represents the current
best link available between genotype and phenotype, and it is these
we analysed further and used as the basis to define four structural
classes of mutations. Subsequently, we have used the approach to
assess ‘Unconfirmed mutations’: those associated with a disease,
but without supporting biochemical evidence (Table 3). The final
goal of this exercise is to allow the pathogenicity of any novel
mutation in Complex III and IV genes to be assessed from the
individual patient sequence data alone (Figure S2).
A Comprehensive Structural Map of Complex III and IV
Mitochondrial Disease Mutations
We revealed that a wide range of pathologies are associated with
mitochondrial-encoded core protein mutation sites of Complexes
IV and III (Figure 2). This is the first visual map, to our
knowledge, of mutation sites found in either single or groups of
patients in mitochondrial proteins. On initial inspection, we reveal
the mutation sites are widely distributed around the core of
Complex IV and Complex III. On closer inspection, more
mutation sites are present in MT-CO1 than the other three
proteins (MT-CO1-2 and MT-CYB). While prostate cancer and
blood disorder mutation sites are specific to MT-CO1, and the
only common metabolic disorder mutation site is specific to MT-
CYB, myopathy and neuropathy mutation sites are present in all
Complex III and Complex IV mitochondrial core proteins.
Mutation sites are also apparent that tend to localize in specific
regions of the subunits. With the sequencing of whole genomes
from affected tissues in individual patients becoming more
common place, there is now an opportunity to build this map
further and develop our understanding of which protein-coding
genes are more susceptible to mutation and whether certain
clusters of mutations are more likely to be associated with either
the same, different or even multiple disease states. It is also
becoming evident from whole genomic studies that affected tissue
from individual patients, for example those with glioblastoma
multiforme, often harbor multiple mitochondrial mutations [22].
There is now a possibility of building structural maps that will
enable us to visualize and predict how functional AAS in
mitochondrial proteins interact within Complexes III and IV
and contribute to metabolic deregulation on a patient-specific
basis.
Systematic Structural Classification as a Platform for
Prediction of Function
We have systematically classified the available mutation data for
Complex III and IV to simplify a complicated and diverse dataset.
Our system takes advantage of current mutation data with
associated biochemistry, the so called ‘confirmed’ set. Although
some previous studies have presented elegant structure-function
examples for individual mutations, such a wide classification, to
our knowledge, has not been previously reported. This allowed us
to identify new patterns and associations that can in turn be used
to predict the functional outcome of those mutations that currently
lack biochemical analysis. We have identified four main structural
and functional classes, and although there can be interplay
between each group; generally, individual mutations fall clearly
into a single class. Here we present detailed illustrations of
confirmed mutations in each class and demonstrate how they can
be used as a basis for predicting pathogenic outcomes and
mechanisms of unconfirmed mutations, as well as for providing
novel targets for drug design. Detailed illustrations of unconfirmed
mutations in each class are also provided. In total, we classified
and predicted the pathogenic potential of 12 confirmed and 7
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unconfirmed mutations, which are available as a resource in
Tables 2 and 3.
Frameshift (Class 1) Mutations cause Protein Subunit Loss
Several diseases have been associated with mutations that
disrupt the register of the triplet coding sequence of the
mitochondrial genome (e.g. Chronic Progressive External Oph-
thalmoplegia [32], Exercise Intolerance [33] and Rhabdomyolysis
[34]). Whether an insertion or a deletion, this inevitably results in
the generation of a stop codon and premature termination of the
amino acid chain. The structural outcome of such mutations can
be catastrophic resulting in the loss of entire domains within the
protein complex. Figure S3 depicts the structural consequence of
the confirmed mutation 6020del5 and how it could contribute to
the pathogenicity of Motor Neuron Disease [35]. In the wild type,
the MT-CO1 subunit maintains much of the catalytic environ-
ment for Complex IV (Figure S3A and C). This mutation results in
the change of 4 amino acids and the loss of 90% of this subunit,
which occurs in both halves of this dimeric complex (Figure S3B
and D), reducing Complex IV activity by almost 60% (Table 2). It
is likely that the nuclear subunits that decorate the surface of this
subunit will not have sufficient surface area to make stabilizing
contacts and will be lost into the membrane. This more general
loss of quaternary structure will further compromise the activity of
the MRC where associations between the complexes have been
demonstrated to be vital for efficient electron transport and for
their assembly and stability [36]. This is borne out by associated
activity loss in other complexes in the chain (Table 2).
Active Site (Class 2) Mutations Disrupt the Local Chemical
Environment
Complexes I, III, IV and V of the MRC have evolved elegant
functional mechanisms to pump protons across the inner
mitochondrial membrane by linking multiple substrates with co-
factors and metallo-protein sites, while maintaining ROS protec-
tion and an efficient environment for local chemistry to take place.
While it is well documented that even small perturbations in these
active site regions of Complex III and IV have functional
Figure 2. A new structural map of human mitochondrial disease mutation sites in Complexes III and IV. Mitochondrial diseases result in
diverse pathology, and can be multi-systemic or tissue-specific. Here we show 93 individual mutation sites mapped onto their corresponding 3D
crystal structures. Each mutation site is shown as a sphere colored according to the primary pathology or tissue (see legend) found to be affected in
either single or groups of patients. The complete dimeric Complex IV is depicted as a ribbon model (A) with the mitochondrial-encoded subunits, MT-
CO1 (B), MT-CO2 (C) and MT-CO3 (D), colored orange, yellow and green, respectively. The three COX monomers are shown separately for clarity. The
dimeric Complex III is shown in the same format (E) with the mitochondrial-encoded MT-CYB (F) subunits colored as blue ribbons.
doi:10.1371/journal.pone.0069003.g002
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consequences (see references in Table 2), Figure 3 illustrates two
cases from numerous examples in the database, the first represents
a confirmed mutation with associated biochemistry and the second
represents an unconfirmed mutation.
Mutation T6742C in Complex IV causes the amino-acid
substitution I280T and is associated with Acquired Idiopathic
Sideroblastic (AIS)-Anemia [37]. Detailed studies of this mutation
have been carried out using artificially generated cybrid cell lines
that harbor the change [38]. Such studies represent a standard
methodology for looking at the effect of mutated mtDNAs on a
relevant nuclear background, but one that requires significant
endeavor and is simply not practical for all mutations (reviewed
[39]). In this case, cybrids that harbor I280T demonstrate a
reduction of approximately 40% in Complex IV activity with a
concomitant loss of 25% activity in Complex III, again
demonstrating the intimate biochemical relationships between
complexes of the MRC (Table 2).
On first inspection, it would seem surprising that such a small
substitution from I to T, constituting the loss of a methyl and the
gain of a hydroxyl group in a very large structure, would have any
effect at all. It is only when the active site environment of subunit
MT-CO1 in Complex IV is examined that the proximity to the
heme group and the contribution to the chemical environment is
revealed (Figure 3A&B) [13]. Heme a3 and CuB form the O2
reduction site in Complex IV and comparison of multiple high-
resolution crystal structures indicates that the cavities in the
immediate vicinity of this heme undergo conformational change as
a function of the oxidation state [40]. In chemical terms, the
substitution of the hydrophobic side chain of I280 with an
uncharged polar side chain of T280 is likely to destabilize the
heme a3 and surrounding cavities, particularly given the proximity
of the hydroxyl group to the tail of heme a3 (Figure S5A&B) [41].
It is therefore clear how this mutation can cause such a significant
and observable functional effect. When considering that this
situation can be amplified to a significant proportion of
mitochondria in all cells, it becomes apparent how a single
mutation can result in metabolic dysfunction and could contribute,
in this case, to AIS-Anemia.
We can use this structural information to predict the effect of
unconfirmed active site mutations that do not have detailed
associated biochemical studies. Figure 3 also shows a second
mutation site in the MT-CO1 subunit that, despite being 100
amino acids away in primary sequence terms, maps within the
same heme pocket as the previous example. Mutation G7041A has
been found in patients with prostate cancer [19]. In this case, the
substitution from V380I represents only a single carbon atom
extension of the side chain (Figure 3A&B). Again, it would seem
surprising that this alone could cause such a dramatic functional
effect, until we observed that this additional carbon atom in our
model creates a direct steric clash with the central Fe a3 atom of
the heme group (Figure S5C and D). This small helical region,
referred to as helix X in the wider literature, is known to undergo a
conformational change responding to the redox state of the heme.
This is in turn linked to the 3D architecture of the water channel
near the hydrogen-bond network junction required for efficient
proton-pumping [40,41].
Mapping of two more confirmed mutations (T6721C [38] and
G6955A [42]) to Heme a3 further underlines that the environment
around this catalytic metal is highly sensitive to even sub-angstrom
perturbations (Figure S4). We therefore predict that the biochem-
ical outcome of the G7041A will be a significant loss of Complex
IV activity due to disruption of the catalytic heme and surrounding
area. This in turn may contribute to the shifts in energy
metabolism from oxidative phosphorylation to glycolysis, often
observed in tumor cells, and may play a significant role in the
progression of the disease. This example illustrates how the
mapping of confirmed mutations in a structural context can be
used to inform others that are not obviously linked at the level of
primary sequence, or even disease, to aid our understanding of
disease mechanisms and develop new research questions. Consis-
tent with our own predictions based on 3D structural analysis, all
three standard algorithms predict this and other confirmed and
unconfirmed Class 2 mutations as pathogenic (Table 2 and 3).
This is due to these Class 2 mutation sites being highly conserved
between multiple species. In both examples presented here, I280
and V380, these residues are 100% conserved among the 6
vertebrate and 4 invertebrate MT-CO1 sequences used by SIFT
in the integrated approach [27].
Binding Pockets (Class 3) Mutations could Explain Patient
Sensitivity to Substrates and Inhibitors
Recent advances in electron microscopy have revealed the
direct association of MRC complexes within the inner mitochon-
drial membrane [36,43,44], however, it is well established that
Figure 3. Active site mutations. (A) The active site region of the wild-type MT-CO1 subunit of complex IV is depicted as a ribbon diagram with key
amino acids as orange stick representations (within red circles). The heme a3 is colored in green with the Fe atom in grey. (B) Two separate mutations
have been modeled, I280T and V380I. More detailed diagrams can be found in Figure S5.
doi:10.1371/journal.pone.0069003.g003
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many of the interactions between the complexes are the result of
the shuttling and modification of small molecules [4]. Each
complex has multiple binding pockets that can accommodate both
substrate and product and these cavities can be exquisitely formed
to be highly selective. Such properties represent attractive targets
to the pharmaceutical industry. Often these pockets are formed in
3D space from multiple regions, chains or subunits, not obviously
proximal when relying on 2D sequence alignments. Again, it is the
ability to map mutation sites onto high-resolution structures that
yields direct insight into the mechanisms of subtle disease
associated mutations [8]. Figure S6 and 4 depict in detail two
such examples in the ubiquinone (Coenzyme Q) binding pocket
(Qi site) of MT-CYB, one confirmed, T14849C (S35P), and one
unconfirmed, A14841G (N32S), associated with Septo-Optic
Dysplasia [45] and LHON [21], respectively. The locations of
further confirmed binding pocket mutations, one in the Qi site
(G14846A [33]) and two in the ubiquinol binding pocket (Qo
site)(A15579G [46] and G15762A [47]) are shown in Figure S4.
The intricate cavity of the Qi site, visualized by the surface
rendering in Figure S6C, is formed by a cluster of alpha-helices
that together generate an access tunnel from the external
environment to the internally located heme bH. The Qi site has
a complex role that is optimized to allow efficient reduction and
protonation of the ubiquinone substrate. This is achieved by
selective substrate binding in a coordination compatible for
electron transfer with the heme bH while maintaining connection
with the mitochondrial matrix for the supply of protons. Such
interactions are highly evolved and even subtle changes can
drastically alter binding. For example, Antimycin A, a natural Qi
site inhibitor, also binds within this cavity with high affinity and
competes with ubiquinone [48]. Studies in the highly related
complex from Leishmania tarentolae have shown that a subtle S35I
mutation confers resistance to Antimycin A, clearly demonstrating
the contribution of individual amino acids to selective substrate
binding within this pocket [49].
In a human patient with Septo-Optic Dysplasia [45], the S35P
substitution at the same position can be considered to be more
dramatic than the protozoan S35I substitution in terms of amino
acid chemistry. It is likely to generate a severe structural
perturbation by inserting P35 into a major helix (helix A) that
lines the pocket, in addition to the loss of a hydrogen bond to
ubiquinone originally reported [45]. Proline is unusual, being a
secondary amine with a cyclic structure that results in a
conformational rigidity, and cannot easily participate within an
alpha helical fold as it disrupts helical hydrogen-bonding and
generates steric incompatibility. It is likely that this mutation will
disrupt the correct folding of this alpha helix at the point where it
forms the integral surface of the binding pocket. The affected
region is depicted as the red surface rendering in Figure S6D. This
will disturb ubiquinone-mediated electron transfer from heme bH
and the production of ubiquinol. The observed biochemical
outcome is a reduction of Complex III activity by 49% and a
significant concomitant drop in the activity of all the other MRC
complexes tested (Table 2). Deficiency in ubiquinone or ubiquinol
is likely to disrupt the Q-cycle mechanism that involves electron
transfer from ubiquinol at the Q0 site to Cytochrome c and
ultimately Complex IV, explaining the deficiency in both Complex
III and IV.
The unconfirmed N32S substitution associated with LHON
[21] is situated deep within the Qi-pocket, also on transmembrane
helix A (Figure 4A&B) and this location alone suggests a role in
substrate interactions. Indeed, detailed crystallographic data have
revealed three key H-bonds between residues lining the cavity
surface in this region (D228, H201 and S205) and the ubiquinone
substrate, two of which are water-mediated and thought to be
central to the protonation mechanism [10]. Residue N32
participates in stabilizing H-bonds to the main chain and side
chain of K227 (Figure 4A). Interestingly, K227 is implicated in the
high binding affinity of Antimycin A due to the generation of one
of two additional H-bonds compared to the natural substrate
ubiquinone. It is precisely these fine details that have the potential
to inform drug sensitivities in a patient-specific manner. For
example, in this patient it is likely that the N35S substitution would
reduce the competitive effect of Antimycin A (Figure 4B).
Residue N32 is also proximal to the side chain of D228 which
makes both direct and water-mediated contacts to ubiquinone. It is
therefore likely that the mutation N32S will act in a similar
manner to the confirmed mutation S35P, disrupting the produc-
tion of ubiquinol from ubiquinone and the overall Q-cycle
mechanism, resulting in significant loss of Complex III function
and related detrimental effects to the whole MRC. The predicted
ubiquinone deficiency in patients that harbor Qi pocket mutations,
such as at P35 and S32 sites, could mean they would benefit from
ubiquinone replacement therapy, shown to be effective for known
ubiquinone deficiency disorders that present with childhood
encephalopathy and seizures, recurrent rhabdomyolysis or ataxia
with seizures [50].
Similar to the Class 2 mutations, and consistent with our
predictions, all three standard algorithms predict confirmed and
unconfirmed Class 3 mutations (Table 2 and 3) to be pathogenic.
This is due to the mutation sites occurring at evolutionary
conserved residues. Furthermore, unlike the 3D analysis, the
standard algorithms do not offer a window into the mechanism of
pathogenesis and cannot be used to predict differences in patient
sensitivities to inhibitors and substrates. Nor do they allow the fine
details of the binding pockets to be visualized in 3D space,
providing opportunities for novel drug design. Depending on the
mutation(s) present in binding pockets such as the Qi site, novel
inhibitors that compete with the natural substrate could be
designed to selectively trigger mitochondrially-mediated apoptosis,
proposed as a treatment for some cancers including gliomas [51].
Identification of Novel Nuclear-Mitochondrial Interaction
Region (Class 4) Mutations Requires the Detailed
Consideration of Quaternary Structure and Subunit
Interactions
The 3D structural analysis of disease-associated AAS that result
from mutations in mtDNA Complex III and IV protein-coding
genes has revealed a previously undefined subset we term Class 4,
located at the protein-protein interfaces between the subunits that
make up the MRC complexes. Within this class, those that occur
at the nuclear-mitochondrial interfaces are the most highly
represented within the MITOMAP database. It would seem
obvious that the interacting surfaces of the individual proteins that
make up the complexes are vital for correct assembly, stability and
ultimately function, however, it is these nuclear-mitochondrial
interaction region AAS in particular that can remain invisible to
current in silico pathological predictions. Here we look specifically
at Complex IV as no Class 4 mutations were identified in
Complex III. Only when new complete MRC structural
homologues become available will it become possible to determine
whether such mutations also occur in the other bigenomic
complexes; I and V.
In Complex IV, denaturation studies employing urea and
guanidinium chloride have shown that the individual nuclear
subunits are robust and structurally stable, however, their
interactions within the complex are much less stable [52]. In
Structural Analysis of Mitochondrial Mutations
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particular, 5 of the 13 subunits were shown to be released from the
complex under relatively mild denaturing conditions in the order
COX6B, COX6A, COX7A, MT-CO3, and finally COX5B.
There is now a large body of literature on the role of the individual
nuclear-encoded subunits; however, it is experimentally challeng-
ing to assign specific function in a cellular context. Subunits
including COX4, COX5A, COX5B, and COX6A have been
attributed with ATP-dependent regulatory roles [53] and this is
borne out by the identification of tissue-specific isoforms of several
nuclear-encoded COX subunits [54,55]. Subunits such as
COX6C and COX6B2 appear to have more structural roles
since their untimely removal during biogenesis can render the
entire complex irreversibly monomeric [56].
Figure 5 illustrates a detailed example where a simple amino
acid change results in a sterically incompatible surface between the
MT-CO2 and nuclear-encoded COX6C subunits. Despite this
mutation site being distal from any of the redox machinery, this is
a confirmed AAS and the resulting loss of structural integrity is
associated with a 75% loss of Complex IV activity and a myopathy
[57] (Table 2). The M29K change on the surface of MT-CO2
places an extended charged side-chain in a region where each
surface otherwise presents a complementary array of hydrophobic
residues. Not only is this mutation sterically incompatible with this
intimate subunit-subunit interaction, but the basic, polar and
highly hydrophilic nature of lysine makes its accommodation in
this environment extremely energetically unfavorable. It is likely
that the stability of the pair of COX6C subunits in the Complex
IV dimer will be affected, and their loss could render a normally
protected catalytic mitochondrial-encoded subunit exposed and in
direct contact with the harsh ROS-rich environment of the
membrane.
Several unconfirmed Class 4 mutations have been identified in
the MT-CO1 subunit of Complex IV that are associated with
prostate cancer (G6261A, A7158G, G6480A and T6253C)
[6,19,20,58,59]. Figure S8 highlights mutation T6253C which
causes a M117T substitution in MT-CO1. The change from a
Met to a Thr in rhodopsin protein is a known contributor to
retinitis pigmentosa in humans [60]. Structural analysis of this
mutation reveals that this Met side-chain is intimately involved in
multiple hydrophobic interactions in the core of rhodopsin and
plays a central role in its stability. Not in the core, but similarly
surrounded by hydrophobic residues, M117 in Complex IV
occupies a key position on the surface of MT-CO1 and interacts
directly with not one, but two nuclear-encoded subunits, COX7C
and COX7A1. This hydrophobic junction is likely to be critical to
the correct assembly of the nuclear-encoded subunits around the
core and AAS such as M117T are likely to undermine these
interactions. This could result in a loss of stability, or, as depicted
in Figure S8D, the complete loss of the two pairs of nuclear
subunits. The precise role of COX7A1 is not yet clear, however,
two recent studies in mice reveal that a COX7A1 knockout gives
rise to a cardiomyopathy phenotype with reduced Complex IV
activity but increased ATP production [55] while a deletion of the
heart-isoform of COX7A1 impairs muscle angiogenesis and
OXPHOS [61]. Interestingly, COX7C has been shown to be
phosphorylated and may play a signaling role [62] and in a
separate study, the expression of COX7C was identified as one of
several proteins regulated in the switch between glycolysis and
OXPHOS in tumor cells [63]. In either case, it would appear that
loss of one or both of these subunits from Complex IV would have
a direct impact on the biochemistry of the MRC and could
predispose the cells towards a metabolic situation that promotes
tumor growth.
From the 3D structural analysis, a further six unconfirmed Class
4 mutations are predicted as pathogenic, while only 3/7, 2/7 and
1/7 are predicted by MutationAssessor, SIFT and Polyphen,
respectively (Table 3 and Figure S7). This result indicates that
nuclear-mitochondrial interaction (Class 4) mutations are not
readily detected by current algorithms. This is often because these
sites are distal from what are considered catalytically important
regions, but more significantly, these sites are subject to the co-
evolution of interacting surfaces within each species [64,65]. MRC
subunit compatibility is a product of millions of years of co-
evolution between nuclear and mitochondrial genomes [66] and,
at least in evolutionary terms, mutations on one surface can
eventually be accommodated by a compensating mutation on the
interacting surface. Since current algorithms rely on conservation
to identify residues of key functional importance, pathogenic
mutations can be easily missed when using multiple sequence
alignments from a wide range of organisms. As discussed
previously, the human active site residues are often completely
conserved between diverse species and even lower organisms. In
stark contrast to this situation, the Class 4 residues are generally
much less conserved. Even in MT-CO1, considered to be the most
highly conserved of all the mitochondrial-encoded genes [67],
these interacting residues often have identities of 50% or less
Figure 4. The role of residues contributing to substrate-binding cavities. MT-CYB has several deep pockets for binding, redox interaction
and modification of substrates. (A) The Qi site is formed by the contribution of multiple helical regions (blue) that fold around heme bH (green) while
maintaining contact with the solvent. The wild-type residue N32 (PDB 1NTZ) is shown making hydrogen bonds (dotted lines) with the natural
substrate ubiquinone (orange), within the same pocket. (B) Mutation to S32 results in the loss of key hydrogen bonds previously identified to be
crucial in the redox mechanism.
doi:10.1371/journal.pone.0069003.g004
Structural Analysis of Mitochondrial Mutations
PLOS ONE | www.plosone.org 10 July 2013 | Volume 8 | Issue 7 | e69003
within the reference alignment used in current tools [27].
Furthermore, lower organisms generally possess a less numerous
cohort of accessory subunits, some of which are vital for regulated
function in higher eukaryotes.
Conclusion
The systematic 3D structural analysis of disease-associated
mutations in Complex III and IV mtDNA protein-coding genes
enabled us to generate a comprehensive visual structural mutation
map and identify a novel class that currently eludes existing
predictive approaches. This finding suggests that interaction
region mutations play a far greater role in human diseases than
previously thought and highlights the need for the bigenomic,
quaternary structural organization of the mitochondrial respira-
tory chain to be taken into consideration when predicting the
functional importance of amino-acid substitutions. 3D structural
analysis provides the opportunity to visualize and predict the effect
of multiple amino acid substitutions, information that could be
utilized by the pharmaceutical industry to inform the development
of new or improved treatments for mitochondrial diseases, perhaps
on a patient specific basis in the future.
Methods
Data Collection
The RCSB PDB was mined for homologous MRC structures
using all 13 peptide sequences from the revised Cambridge human
reference mtDNA genome (NC_012920). Sequence alignments
were performed using ClustalW [68] and annotated using ESPript
[69] (Figure S1).
PyMOL (Schro¨dinger, LLC) was used to identify and display
the available X-ray crystallography data for the five protein
complexes of the MRC, highlighting the nuclear and mitochon-
drial-encoded chains. The models for each complex were derived
from the following X-ray crystallographic data; Complex I
(NADH dehydrogenase) 4HEA and 3M9S [2,70], Thermus
thermophilus; II (succinate dehydrogenase) 1ZOY [71]; Sus scrofa,
III (cytochrome bc1) 1BE3 [8], Bos taurus; IV (cytochrome c oxidase)
1OCC [72], Bos taurus; V (ATP synthase) 1C17 [73], Escherichia coli
and 1H8E, Bos Taurus [74].
As Complex III and IV are paradigms of how intimate nuclear-
mitochondrial interactions generate complex functional machines
and are highly conserved between the bovine and human
Figure 5. Assembly disruption from bigenomic protein incompatibility in Complex IV. (A) The mitochondrial subunits are surrounded by
nuclear-encoded subunits that make intimate interactions, in this case MT-CO2 (yellow ribbons) with COX6C (purple ribbon), respectively. The wild
type M29 residue is shown in stick form occupying a position between to aromatic side chains from COX6C. (B) The mutation K29 results in the
incorporation of a long and polar side chain that is incompatible within the tight interface between MT-CO2 and COX6C. (C) The wild type-enzyme is
shown as a surface model in the same color scheme with the position of the mutation site highlighted by a dotted red circle. (D) A surface illustration
depicts the position of the K29 mutation and the potential resulting aberrant assembly of the nuclear subunit COX6C.
doi:10.1371/journal.pone.0069003.g005
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homologues with sequence identities of 78, 91, 75 and 88% for
MT-CYB and MT-CO1-3, respectively (Table 1), the MITOMAP
database was mined for mutations in corresponding mtDNA genes
with published disease associations (http://www.MITOMAP.org/
MITOMAP [75]).
For a subset of mutations, individual MRC complex activity and
O2 consumption data were collated from the literature (Tables 2).
Activities were measured either polarographically or spectropho-
tometrically in patient muscle samples and or cybrids containing
specific mutations, and are expressed relative to published mean
control values. Where mean control values were unavailable, they
were calculated from published control range values.
Structural Mapping and Analysis
Ninety three point mutation sites in mtDNA Complex III and
IV genes were mapped onto their corresponding bovine crystal
structures based on the primary sequence alignments as a function
of pathological grouping. For the subset of mutations with
complex activity data, detailed analysis of the location, relative
to important catalytic and/or interaction surfaces, and the
potential effect of each mutation site was performed using COOT
[76]. This subset was then used to define four structural classes of
mutation: 1) Frameshift, 2) Active Site, 3) Binding Pocket, and 4)
Nuclear-Mitochondrial Protein Interaction Region and predict the
pathogenic potential of a further subset of mutations for which
there was no activity data available.
Comparison with Other Predictive Tools
The 3D structural analysis was compared with following
predictive approaches: 1) the recently published integrated
approach that uses SIFT (http://sift.jcvi.org/www/
SIFT_related_seqs_submit.html) and PolyPhen (http://genetics.
bwh.harvard.edu/pph2) programs [27] and 2) the MutationAs-
sessor program (http://mutationassessor.org/v1/) [77] (Tables 2
and 3). SIFT predictions were obtained by submitting the human
MT-CO1-3 and MT-CYB sequences along with the 10 species
recommended by the integrated approach: Homo sapiens, Bos taurus,
Mus musculus, Rattus norvegicus, Gallus gallus, Xenopus laevis, Drosophila
melanogaster, Strongylocentrotus droebachiensis and Caenorhabditis elegans,
and the substitutions of interest. SIFT then generated an
alignment and assigned a score to each substitution ranging from
zero to one. Substitutions with a SIFT score of ,0.05 were
predicted to affect protein function, while those .0.05 were
predicted as tolerant (not likely to affect protein function).
Polyphen predictions were also obtained by submitting the four
human mitochondrial protein sequences along with the substitu-
tions of interest. Polyphen then assigned scores to each
substitution, ranging from zero to a positive number, using protein
sequences from the UniProtKB/UniRef100 Release 2011_12 (14-
Dec-2011), structures from the PDB/DSSP Snapshot 03-Jan-2012
(78,304 entries) and multiple alignments (UCSC MultiZ) of 45
vertebrate genomes with hg19/GRCh37 human genome (08-Oct-
2009). Substitutions with a score of zero were predicted as benign,
while substitutions with a positive number were predicted as
pathogenic. MutationAssessor predictions were obtained by
submitting the Uniprot protein accession numbers for the four
human mitochondrial proteins and the substitutions of interest.
MutationAssessor then generated an alignment using Uniprot and
Refseq protein sequences and assigned a score to each substitution.
MutationAssessor predicted substitutions with a score of .3.5,
3.5–1.9, 1.8–0.8 and, ,0.8 as high impact, medium impact, low
impact and neutral, respectively.
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Figure S1 Sequence alignment of human vs bovine
complexes used in the 3D structural analysis of amino
acid substitutions in Complex III and IV mitochondrial-
encoded subunits, shown in Table 2 and 3.
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Figure S2 3D structural analysis flowchart used for the
classification and pathogenic prediction of mutations in
the mtDNA complex III and IV genes (mt-cyb and mt-
co1-3, respectively) reported with human disease asso-
ciations, with and without known biochemical effects,
see Table 2 and 3.
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Figure S3 Structural consequences of a frameshift
mutation, further details in Table 2.
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Figure S4 The position of 10 individual mutations found
within an active site region of MT-CO1 and a binding
pocket of MT-CYB of Complex IV and III, respectively,
details in Table 2 and 3.
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Figure S5 Detailed view of active site mutations I280T
and V380I, further information on predicted pathoge-
nicity can be found in Table 2 and 3.
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Figure S6 Substrate-binding cavity mutation S35P,
further details on their biochemistry and predicted
pathogenicity can be found in Table 2.
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Figure S7 Interaction region (Class 4) mutations in
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